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Abstract
Purpose Radiolabelled interleukin-2 is a radiopharmaceu-
tical used for the study of chronic inflammatory processes.
123I-labelled interleukin-2 has successfully been used in a
large number of patients affected by several immune-
mediated diseases. 123I, however, is expensive and not
readily available. We have, therefore, developed a method
for labelling interleukin-2 with 99mTc to high specific
activity based on the use of an N3S bifunctional chelating
agent. In this paper, we describe the results obtained with
99mTc-interleukin-2 in a series of eight normal subjects and
of 12 patients with autoimmune thyroid diseases.
Methods Biodistribution, pharmacokinetics, haematological
and systemic toxicity, radiation absorbed dose and in vivo
targeting were studied.
Results Results showed rapid plasma clearance of 99mTc-
interleukin-2 with retention mainly in the kidneys. Biodis-
tribution and kinetics were similar to that observed for
123I-interleukin-2. No acute systemic toxicity was found; a
small decrease in peripheral blood lymphocytes was
observed in the first hours only in patients, but it was mild
and transient. 99mTc-interleukin-2 accumulated, to varying
extents, in the thyroid of all patients affected by autoim-
mune thyroid diseases but not in the thyroid of normal
subjects. The effective dose equivalent of a diagnostic
activity of 99mTc-interleukin-2 (185 MBq) was 1.35 mSv.
No correlation was observed between thyroid autoanti-
bodies and uptake of 99mTc-interleukin-2.
Conclusions The use of 99mTc-interleukin-2 is safe and
simple; the favourable dosimetry and biodistribution and
the rapid clearance make it potentially useful for the study
of chronic inflammatory diseases such as autoimmune
thyroid disease.
Keywords 99mTc-IL2 . Autoimmune thyroid diseases .
Infiltrating lymphocytes . Dosimetry
Introduction
Radiolabelled interleukin-2 (IL2) is a radiopharmaceutical
designed for the in vivo study of chronic inflammatory
diseases [1]. Previous studies with 123I-labelled IL2 (123I-
IL2) in several patients with immune-mediated diseases
showed specific targeting of tissues-infiltrated by activated
lymphocytes; rapid clearance from the circulation through
the kidneys was observed, and major organs of uptake were
kidneys, liver and spleen with minimal intestinal excretion.
No side effects were reported [2, 3]. Radiolabelled IL2
might be a useful radiopharmaceutical in different immune-
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mediated diseases: it might guide the diagnosis and
treatment of the disease by providing relevant information
about the presence of the ongoing inflammatory process.
The efficacy of new, specific, anti-inflammatory drugs
could also be tested. It would be necessary, however, to
perform studies in an adequate number of patients to
evaluate the clinical value of radiolabelled IL2 in different
diseases. 123I, however, is expensive and not readily
available, and 99mTc labelling of IL2 would be desirable
for larger studies.
We have previously described a technique for 99mTc
labelling of IL2 using a N3S bifunctional chelating agent
with purification by solid phase extraction [4]. The aim of
this study was to describe the biodistribution and kinetics of
99mTc-IL2 in normal subjects, the potential toxic profile and
the radiation absorbed dose. We also studied the ability of
99mTc-IL2 to detect in vivo areas of lymphocytic infiltration




Radiolabelling of IL2 was carried out under aseptic
conditions. Interleukin-2 was labelled with 99mTc using a
two-step pre-labelling method as previously described [4]
using a bifunctional chelating agent with two functional
sites: an N3S ring, similar to that of MAG3, for the stable
coordination of 99mTc, and an active ester for binding to
proteins via the amino groups of lysine residues. Briefly,
the ligand was first labelled to high specific activity with
99mTc (3.7 GBq) in the presence of stannous chloride and
gluconic acid at pH 2 at 80°C for 20 min. Radiolabelled
ligand was then conjugated to IL2 (100 μg, 1 mg/ml) at pH
9 for 40 min at room temperature. 99mTc-IL2 was purified
by solid phase extraction using a step-gradient elution with
acidified ethanol. The radiochemical purity was also
evaluated by thin-layer chromatography using ITLC-SGB
strips (Gelman) and a scanning radiochromatograph. The
strips were developed in acetone for measuring the
presence of free 99mTc. The strips were run in 12%
trichloracetic acid (TCA) for measuring technetium colloid
formation. Before injection into the patient, 99mTc-IL2
(0.5 ml in phosphoric acid acidified ethanol) was diluted
in 5 ml of a 5% glucose solution containing 0.3% of HSA
(final pH 6).
In vivo studies
Informed consent was obtained from all patients and
normal subjects studied. Approval for the project was
obtained from the local Ethics Committee. Confidentiality
of patient identification and data were maintained. Ten
minutes before the study, normal subjects and patients
received 200 mg of sodium perchlorate i.v. to prevent
thyroid and stomach uptake of free 99mTc possibly
generated by the metabolism of 99mTc-IL2.
Studies in normal volunteers
Eight healthy human volunteers (age 29.3±5 years, six males
and two females) were injected with 99mTc-IL2 (16.1±8.9 μg,
42.6±13.9 MBq). Normal subjects, as requested by the
ethics committee and in accordance to the guidance of
ICRP62, were injected with a lower activity of 99mTc-IL2,
compared to patients, since in normal subjects the expected
level of benefit is minimal and the level of exposure must be
in category IIa (effective dose between 0.1 and 1 mSv).
Dynamic images were acquired posteriorly for 45 min over
the heart, liver, spleen and kidneys; static planar images of
the chest and abdomen were obtained at 1, 2 and 4 h. Whole-
body and thyroid scans were also acquired at the same time
points, and radiation absorbed dose was calculated as
described below. Heart rate, body temperature and blood
pressure were monitored through the first hour of the study.
Serial blood samples at 5, 10, 15, 25, 35, 45, 60, 75, 120
and 240 min were taken to measure the plasma pharmaco-
kinetics of the tracer, and TCA precipitation of plasma
samples was performed. Blood samples taken 1, 3, 24, 72
and 132 h after the injection were used to investigate
possible pharmacological effects of interleukin-2 on white
blood cell count. Liver function tests, urea and electrolytes
were also analysed before and 3 h after the injection. In one
subject, a blood sample at 1 h was studied to determine the
distribution of radioactivity in the whole blood.
Serial urine samples were taken up to 4 h for calculation
of excreted activity and dosimetry calculations. Urine
samples were precipitated with TCA for evaluation of
99mTc-IL2 metabolism.
Studies in patients
Eight patients with Hashimoto thyroiditis, three with
Graves’ disease and one with primary hypothyroidism were
studied. Diagnosis was based on the presence of thyroid
autoantibodies (anti-thyroid peroxidase, anti-TSH receptor
and anti-thyroglobulin), measurement of hormones (FT3,
FT4 and TSH), 99mTc-pertechnetate thyroid scan and
clinical findings. At the time of the study, patients were
recently diagnosed and were not receiving anti-thyroid
drugs or other medications known to have an effect on
lymphocyte activation.
Patients were injected i.v. with 110.2±96.9 MBq of
99mTc-IL2 (40.2±11.7 μg). After the injection, dynamic
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images were acquired posteriorly for 45 min over the heart,
liver, spleen and kidney. Static images were acquired at 1
and 3 h over the thyroid. Thyroid uptake of 99mTc-IL2 was
calculated by drawing a rectangular region of interest (ROI)
around the organ; thyroid net counts were measured after
subtraction of background activity calculated in a second
rectangular ROI two pixels larger around the first; absolute
thyroid uptake was calculated by converting the thyroid
counts in activity according to the counting efficiency of
the individual gamma camera. A semi-quantitative mea-
surement of thyroid accumulation of 99mTc-IL2 was also
determined by calculating the thyroid to background ratio
by drawing an irregular ROI over the thyroid and a
rectangular ROI above the thyroid.
Blood samples were taken before and 10, 20, 40, 60 and
180 min after the injection of the radiopharmaceutical for
calculation of blood clearance, TCA precipitation of plasma
samples and evaluation of possible pharmacological or
toxic effects.
Dosimetry calculations
In normal subjects, a set of anterior and posterior whole-
body images, including a standard of known radioactivity,
was acquired on a 512×512 matrix at different time points
(typically 1, 2, 4 h) after administration of the radiophar-
maceutical. Counts determined from the computer images
corresponding to regions of interests drawn for the liver,
spleen, kidneys, bladder and the standard were converted to
activities.
The uptake in each organ was considered to be
instantaneous; the clearance curves were obtained from
the geometric mean of the anterior and posterior mono-
exponential fit to the activity–time curve corresponding to
each of the above organs. The activity at time zero and the
mean residence time from these clearance curves were then
used in conjunction with the MIRD dosimetry system (IBM
compatible, MIRDOSE 3, from Oak Ridge Associated
Universities, 1994) to calculate the absorbed dose to each
organ of interest, as well as to the whole body.
Measurement of urine excretion of 99mTc-IL2
Urine was collected at 1, 2, 3 and 4 h after the injection
of 99mTc-IL2. For each collection, the total volume
excreted was measured, and 1 ml was counted for
radioactivity using an automated gamma counter (Ultra-
gamma, LKB). The percentage of administered activity
excreted in the urine was determined by measuring total
excreted radioactivity compared with total activity
injected after correction for decay from the time of
measurement of the injected activity and for counting
efficiency of the gamma counter (71%).
Results
Preparation of 99mTc-IL2
The ligand was labelled to high specific activity with a
labelling efficiency (LE) of 99% with no colloid formation.
IL2 was labelled typically with a LE of 30%; about 30% of
IL2, however, was retained by the cartridge, and the final
labelling yield, after several passages and 2-h preparation,
was about 10%. Starting with 3.7 GBq, the specific activity
of 99mTc-IL2 was about 5.7 MBq/μg. Quality controls
showed a radiochemical purity greater than 95% and the
absence of pyrogens and of microbial contamination.
Studies in normal volunteers
Studies in normal subjects showed fast plasma clearance.
Kidneys were the major organs of accumulation of 99mTc-
IL2; the uptake increased up to 1 h and declined thereafter.
Liver and spleen were also detectable. Some excretion in
the bowel but no uptake in the thyroid or any other organ
was observed (thyroid to background ratio: 1.06±0.05;
Fig. 1, Table 1). TCA precipitation of plasma showed that
most circulating radioactivity at 1 and 4 h was associated
with 99mTc-IL2 (Fig. 2). TCA precipitation of the urine
showed a lower degree of protein-bound radioactivity
compared to plasma (Fig. 2). Cumulative urinary excretion
of 99mTc-IL2 4 h p.i. was 26±5.7% of administered activity.
Analysis of the distribution of radioactivity within whole
blood revealed that 1.3% was associated with the WBC,
10% with the RBC and 88.7% with the plasma.
Fig. 1 Anterior view of the neck showing no uptake of 99mTc-IL2 in
the thyroid region of a normal subject (left) and in a patient with
Hashimoto thyroiditis (right)
Table 1 Rate of clearance of 99mTc-IL2 from different organs and
tissues (in minutes)
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No adverse effects from this dose of IL-2 were seen; no
changes in heart rate, body temperature and blood pressure
were observed; haematological changes were transient and
within normal limits (Fig. 3). No changes in platelet counts
were observed. The effective dose equivalent (EDE) was
calculated to be 7.3 μSv/MBq, i.e. 1.35 mSv for a typical
diagnostic scan (185 MBq; Table 2).
Studies in patients
With respect to normal subjects, a higher accumulation of
the tracer was observed in the spleen and liver of all
patients (Fig. 4). No accumulation in other abdominal
organs and minimal intestinal excretion up to 3 h was
observed (Fig. 5). TCA precipitable activity of sera at 1 h
was mostly protein bound (90.5±5.6%). Haematological
changes were transient and within normal limits (Fig. 3).
No changes in platelet counts were observed. No side
effects were observed.
Studies in patients showed a significant but variable
degree of accumulation of 99mTc-IL2 in the thyroid of all
patients with autoimmune thyroid diseases (Table 3, Fig. 6;
Fig. 2 TCA precipitation of 99mTc-IL2 in plasma and urine at
different time points in normal subjects
Fig. 3 Effect of 99mTc-IL2 on
granulocytes (top graphs), lym-
phocytes (bottom graphs) in
normal subjects (on the left) and
in thyroid patients (on the right).
All counts are within the normal
range
Eur J Nucl Med Mol Imaging (2008) 35:2286–2293 2289
thyroid uptake at 1 h, 0.24±0.09% i.d.; thyroid to
background ratio at 1 h, 1.57±0.21; p<0.0005 vs normal
subjects, Student’s t test). Maximum uptake was seen at
1 h; thyroid uptake at 3 h was reduced by half in most
patients. No correlation was noted between thyroid accu-
mulation of 99mTc-IL2 and autoantibody titre.
Discussion
The diagnosis of patients with autoimmune diseases is
currently based on the measurements of autoantibodies
directed against the target organ [5].
Autoantibodies, however, are indirect markers with
uncertain chronological relation with the underlying im-
mune process as they may persist well after the end of the
process [6]. They often have poor sensitivity since in a
significant number of cases, they are not detectable in
peripheral blood [6]. In vivo imaging of chronic inflamma-
tory processes would help to overcome some of these
limitations by providing direct evidence of the immune
process and might contribute to the management of patients
with autoimmune diseases [7, 8].
123I-labelled IL2 (123I-IL2) has been shown to detect
with high accuracy lymphocytic infiltration in a series of
patients with immune-mediated diseases [2, 3]. Owing to,
however, the cost of 123I-IL2, only a limited number of





Effective dose equivalent is 7.3 μSv/MBq; for a typical diagnostic
activity of 185 MBq: 1.35 mSv.
Fig. 4 Posterior views of summed frames of a dynamic study (0 to
45 min) showing early to late frames (left to right, top to bottom) in a
normal subject (top) and in a patient with Hashimoto’s thyroiditis
(bottom)
Fig. 5 Anterior (left) and posterior (right) whole-body scans in a
patient with Hashimoto’s thyroiditis 3 h after the injection of 99mTc-
IL2
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patients can be studied; 123I, moreover, is not readily
available, and the preparation of 123I-IL2 is a lengthy multi-
step procedure that requires the availability of a dedicated
radiochemistry laboratory. It is, therefore, difficult to
organise multi-centre trials to assess the real role of
radiolabelled IL2 in a suitable number of patients. The
availability of 99mTc-IL2, preferably in the form of a single-
step kit, would greatly simplify the use of this technique.
We have developed a new technique for 99mTc labelling
of IL2 based on the use of an N3S bifunctional chelating
agent with preserved in vitro receptor binding. The
technique described in this paper provided high specific
activity 99mTc-IL2 for clinical use. The labelling procedure
that was developed is multi-step and lengthy and does not
represent a simplification over 123I labelling of IL2. We are
working on a simplified labelling technique with the aim to
formulate a one- or two-step labelling kit.
In this paper, we assess the in vivo use of this new
radiopharmaceutical and describe the biodistribution, kinetics,
dosimetry, toxic profile and targeting capacity of 99mTc-IL2 in
normal subjects and in patients with autoimmune thyroid
diseases.
A low EDE (1.35 mSv for a diagnostic activity equal to
185 MBq) and no toxic effects were observed. This is
particularly important in follow-up studies when repeated
injections are required, especially in view of the possible
use of this radiopharmaceutical in paediatric subjects such
as in patients with juvenile diabetes or coeliac disease.
Studies in human, healthy volunteers showed high in vivo
stability of 99mTc-IL2, higher than previously shown with
123I-IL2, rapid plasma clearance and low background
radioactivity, comparable to that of 123I-IL2. Kidneys were
the major organs of accumulation of 99mTc-IL2, which was
excreted in the urine mostly in the form of low molecular
weight metabolites, confirming previous studies in animals
that demonstrated that IL2 is mainly metabolised in the
kidneys [9]. No intestinal excretion was observed.
Compared to normal subjects, studies in patients showed
an increased level of accumulation of 99mTc-IL2 in the liver
and, to a lesser extent, in the spleen. More than one
mechanism could be advocated for this phenomenon. It is
possible that, following the state of immune activation in
patients with autoimmune diseases, a greater number of
circulating IL2R+ve cells or a greater expression of IL2R is
observed in lymphocytes homing into the liver and in the
spleen. The binding of 99mTc-IL2 to soluble IL2R, which
has previously accumulated by the liver, is also possible, as
well as liver uptake of circulating 99mTc-IL2/sIL2R com-
plexes. The sensitivity of 99mTc-IL2 in pathologies of the
liver and kidneys may, therefore, be reduced owing to its
accumulation in the absence of local pathology. Abbs et al.
have, nevertheless, been able to assess kidney graft
Fig. 6 Thyroid accumulation of 99mTc-IL2, expressed as thyroid to
background ratio in patients with Hashimoto’s thyroiditis, Graves’
disease (and primary myxoedema) and normal subjects
Table 3 Summary of patient clinical data
Patient no. Thyroid uptake (% i.d.) Thy/BKG Anti-TPO autoantib. Sex Age (years) Diagnosis
1 0.32 1.74 320 F 52 Hashimoto
2 n.a. 1.31 320 F 68 Hashimoto
3 0.28 1.75 1280 F 49 Hashimoto
4 0.14 1.4 3500 F 22 Hashimoto
5 0.23 1.90 1750 F 19 Hashimoto
6 0.23 2.05 1280 M 76 Hashimoto
7 0.05 1.55 640 M 37 Hashimoto
8 0.30 1.85 320 M 70 Hashimoto
9 0.13 1.35 40 F 39 Graves’
10 0.27 1.41 160 F 57 Graves’
11 0.28 1.45 640 F 42 Graves’
12 0.29 1.50 1280 F 52 Prim. hypot.
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rejection by 123I-IL2 in a rat model of kidney transplanta-
tion [10].
No thyroid accumulation was seen in normal subjects,
whereas in all patients with autoimmune thyroid diseases, a
significant thyroid uptake of the tracer was observed,
suggesting specific binding to IL2R+ve infiltrating lym-
phocytes. As a consequence of the rapid uptake of 99mTc-
IL2, image acquisition was completed within 2 h. Before
the scan, it was necessary to prepare patients with sodium
perchlorate to avoid possible interferences with free
pertechnetate released by the metabolism of 99mTc-IL2.
This was well tolerated and did not give any side effect.
Thyroid infiltration by activated lymphocytes has been
reported in patients with autoimmune thyroid diseases [11,
12]. Previous studies with 111In-labelled lymphocytes
demonstrated accumulation in patients with Hashimoto’s
thyroiditis but not in patients with Graves’ disease [13].
This may depend on the clonal in situ expansion of
infiltrating lymphocytes in Graves’ disease with no migra-
tion from circulating lymphocytes [12]. In the present
study, however, 99mTc-IL2 accumulated in the thyroid of
patients with Graves’ disease, probably as a consequence
of the easy penetration of a small molecule like IL2 in sites
of chronic inflammation where the vascular permeability is
not greatly increased and access to lymphocytes is more
difficult. Thyroid uptake in patients with Hashimoto’s
thyroiditis was greater compared to that observed in
patients with Graves’ disease. It is known that both diseases
are characterised by lymphocytic infiltration, but in Hashi-
moto’s thyroiditis, the density of thyroid-infiltrating lym-
phocytes is much higher than in Graves’ disease [11, 12].
This is in accordance with our results; a large overlap
exists, however, between the degrees of accumulation of the
radiotracer in the thyroid of either group (Fig. 6), suggest-
ing that 99mTc-IL2 can be used for assessing the activity of
the disease but not for discriminating between Hashimoto’s
and Graves’ disease.
In Graves’ disease patients, a correlation between
microsomal autoantibodies and the intensity of the intra-
thyroidal autoimmune process has been reported [14]. No
correlation was noted, however, in this study between
thyroid accumulation of 99mTc-IL2 and autoantibody titre.
Although no definitive conclusions can be drawn from the
study of this small number of patients, the results obtained
so far suggest that there is no direct correlation between
humoral-mediated and cell-mediated immunity in autoim-
mune thyroid diseases. In the three patients with active
Graves’ disease and exophthalmos, no clear accumulation
of 99mTc-IL2 was noted in the retroorbital space. Lympho-
cytic infiltration of the retroorbital space has been reported
in patients with Graves’ disease, and ophthalmopathy and
the presence of some cytokines (interferon-γ, IFN-γ,
tumour necrosis factor β and interleukin-1α has been
reported in the orbital connective tissue of these patients,
but the presence of IL2 and of IL2R positive cells is still a
matter of debate [15, 16]. It is also possible that a transient,
time-related expression of the IL2R occurs and that
expression of IL2R might only be observed in the early
phases of exophthalmos. This has already been reported for
111In-octreotide, which showed accumulation in the retro-
orbital space of patients with exophthalmos only during the
early phases of the disease [17, 18]. Finally, a sensitivity
problem cannot be ruled out due to the limited amount of
radioactivity (about 100 MBq) injected in our patients.
Indeed, Rendl et al., using 123I-IL2 and injecting much
higher activities (about 370 MBq), were able to image the
retroorbital infiltration, as well as the pre-tibial myxoe-
dema, better than with 111In-octreoscan in patients with
Graves’ disease [19]. A controlled study in a larger number
of patients is necessary to address this point.
Conclusion
These preliminary results suggest that scintigraphy with
99mTc-IL2 is simple and safe. Its rapid clearance and
favourable dosimetry and biodistribution make it a suitable
technique for in vivo imaging of disease activity in patients
with autoimmune thyroid diseases and might be used to
confirm the immune nature in doubtful cases. Larger studies
are in progress in several pathologies to assess the role of
99mTc-IL2 in the clinical management of autoimmune
patients.
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